Valuation: PharmaEngine, Inc.

Market Cap 9.15B 284M 246M 230M 210M 395M 27.07B 402M 2.7B 1.06B 13.55B 1.07B 1.04B 45.21B P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 4.48B 139M 120M 113M 103M 193M 13.25B 197M 1.32B 518M 6.63B 521M 510M 22.12B EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.82%
Yield 2024
6.64%
Yield 2025 2.84%
1 day-1.55%
1 week+2.74%
Current month+3.75%
1 month-1.24%
3 months+10.21%
6 months-1.24%
Current year-9.52%
1 week 62.6
Extreme 62.6
64.7
1 month 60
Extreme 60
70.5
Current year 53
Extreme 53
74
1 year 53
Extreme 53
79.2
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 16/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 18/01/2018
Director/Board Member - 14/05/2018
Director/Board Member - 12/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-1.55%+2.74%-18.23%-23.71% 288M
-0.72%+2.71%+5.66%+15.52% 50.03B
-0.69%+6.25%+492.36%+585.40% 44.36B
+0.08%+11.23%+23.99%+81.74% 40.82B
+0.76%+6.85%+35.40%+10.92% 39.83B
+4.73%+15.53%+26.95%+54.62% 32.51B
-0.41%+4.08% - - 16.85B
+0.51%+5.29%+34.62%+126.87% 16.81B
-0.20%+3.19%+5.18%+18.55% 14.05B
+1.81%+20.45%+89.35%+31.49% 13.22B
Average +0.49%+251.97%+77.25%+100.16% 26.88B
Weighted average by Cap. +0.62%+295.00%+108.06%+139.31%

Financials

2024 2025
Net sales 2.52B 78.26M 67.82M 63.49M 57.93M 109M 7.46B 111M 744M 292M 3.74B 294M 287M 12.46B 911M 28.27M 24.5M 22.93M 20.92M 39.38M 2.7B 40.04M 269M 105M 1.35B 106M 104M 4.5B
Net income 1.75B 54.31M 47.06M 44.06M 40.2M 75.65M 5.18B 76.92M 517M 202M 2.59B 204M 199M 8.65B 388M 12.02M 10.42M 9.75M 8.9M 16.75M 1.15B 17.03M 114M 44.81M 574M 45.14M 44.16M 1.91B
Net Debt -3.85B -120M -104M -96.96M -88.47M -166M -11.4B -169M -1.14B -445M -5.71B -449M -439M -19.04B -4.67B -145M -126M -118M -107M -202M -13.83B -205M -1.38B -540M -6.92B -544M -533M -23.09B
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
10/08/26 NT$63.70 -1.55% 329,056
10/08/26 NT$64.70 +1.57% 520,976
07/08/26 NT$63.70 +0.79% 348,630
06/08/26 NT$63.20 -0.78% 180,510
05/08/26 NT$63.70 +1.11% 446,723
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock